Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Community Fast Track, 2007
    The Protein Engrailed as a Potential Therapeutic Target in Parkinson's Disease

    Promising Outcomes of Original Grant:
    In our original grant, we have confirmed that a protein called Engrailed (which plays an important role both in the developping and in the adult dopaminergic...

  • Community Fast Track, 2007
    CDNF - A Novel Conserved Neurotrophic Factor that Protects Midbrain Dopaminergic Neurons in vivo

    Promising Outcomes of Original Grant:
    Future treatment of Parkinson’s disease aim at therapies which would stop the progress of the disease and restore the function of injured dopamine nerves in the...

  • Biomarkers, 2007
    Prospective Validation of Risk Markers for the Development of Parkinson’s Disease

    Objective/Rationale:
    The development of disease-course modifying or neuroprotective treatments is still an unmet therapeutical need in Parkinson’s disease. Treatment will likely work best if initiated...

  • Therapeutics Development Initiative, 2006
    Preclinical Evaluation of a 5-HT2A Antagonist for Treatment of L-DOPA-Induced Dyskinesias in Parkinson's Disease

    The primary motor deficits of Parkinson's disease are effectively improved by administration of the dopamine precursor L-dihydroxyphenylalanine, or levodopa. For unknown reasons, levodopa loses...

  • Therapeutics Development Initiative, 2006
    Treatment of Parkinson’s Disease with AT2101, a compound that increases the activity of endogenous Glucocerebrosidase

    Genetic association studies have suggested a link between Parkinson's and Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the gene GBA, which results in a loss...

  • Therapeutics Development Initiative, 2006
    PN277: A NEURO- RESTORATIVE, PROTECTIVE PRODUCT FOR PARKINSON’S DISEASE

    Acute and chronic neurodegenerative disorders such as Parkinson's disease, stroke, head trauma, spinal cord injury, Huntington's, Alzheimer's and ALS affect millions of people worldwide. Currently...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.